PVI
CBIO

Pura Vida Investments’s Crescent Biopharma CBIO Stock Holding History

Pura Vida Investments’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-316
Closed -$95.8K – 121
2022
Q4 		$95.8K Buy
+316
New +$46.6K ﹤0.01% 183
2022
Q2 		– Sell
-877
Closed -$100K – 234
2022
Q1 		$100K Buy
+877
New +$103K ﹤0.01% 222

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Pura Vida Investments's CBIO Position: Q1 2023 in Review

Pura Vida Investments sold out of Crescent Biopharma (CBIO) in Q1 2023, closing a stake of 316 shares — an estimated $95.8K sold.

Pura Vida Investments first reported a position in CBIO in Q1 2022 and held it in 2 quarters. The position peaked at $100K in Q1 2022. 54 funds tracked by Wall St. Rank hold CBIO as of Q1 2023.

  • Pura Vida Investments reported no remaining Crescent Biopharma position as of Q1 2023 after selling out during the quarter.
  • Pura Vida Investments sold 316 Crescent Biopharma shares in Q1 2023, an estimated $95.8K.
  • Pura Vida Investments first reported a position in Crescent Biopharma in Q1 2022 and held it in 2 quarters.
  • Pura Vida Investments's Crescent Biopharma position peaked at $100K in Q1 2022.
  • 54 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2023.

Based on Pura Vida Investments's 13F filing for Q1 2023, filed 15 May 2023.